Opsumit Label And Pricing Suggest Actelion’s Gamble Ready To Pay Off
Executive Summary
Actlelion is banking on labeling advantages and strategic pricing to propel sales of its new drug for pulmonary arterial hypertension, Opsumit, even after its best-selling PAH drug, Tracleer, goes generic.
You may also be interested in...
Optimal Labeling For Opsumit Allows Actelion To Drop Promotion Of Tracleer
With a ‘clean’ label that differentiates macitentan from current standard of care, Actelion’s got what it wanted from FDA: a newly approved next-generation drug with a long patent life that can expand its presence in the pulmonary arterial hypertension market, and, importantly, protect its core franchise from upcoming generic competition.
Actelion Braces For Tracleer Patent Cliff With New Drugs, New Data Standards
Actelion is preparing for the patent loss on its leading PAH drug not simply with a new product, but by setting a new efficacy standard across the entire PAH community.
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?